Gollnick H, et al. - Since imiquimod 5% cream (IMIQ) and diclofenac 3% gel (DIC) are commonly used to treat actinic keratosis (AK), however, their long-term impacts after repeated therapy cycles have never been contrasted, researchers conducted this pooled analysis of two randomized controlled trials to compare IMIQ and DIC in AK treatment with the risk of grade III AK or invasive squamous cell carcinoma (SCC) change after 3 years. Immunocompetent adults with 5–10 noticeable AK lesions on the face/scalp and grade I/II AK were eligible for incorporation. A total of 479 patients (IMIQ 242; DIC 237) were included in the full analysis set. The authors concluded that IMIQ has been superior to DIC in clearing AK lesions and preventing histological change to grade III AK or invasive SCC and recurrence over 3 years. Both treatments have been tolerated well.